Compare Intuit Inc. (INTU) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuit Inc. vs Viatris Inc — how do they compare? Intuit Inc. trades at $290.14 (market cap $80.37B), while Viatris Inc trades at $17.36 (market cap $19.79B). The key difference: Intuit Inc. is far larger — about 4.1× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| INTU | VTRS | |
|---|---|---|
Market Cap | $80.37B | $19.79B |
Sector | Technology | Health |
52-Week High | $807.39 | $17.39 |
52-Week Low | $255.07 | $8.74 |
Enterprise Value | $78.83B | $32.00B |
Dividend Yield | 1.63% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuit (INTU) trades at $291.09, down 1.26% over the past day, amid mixed technical signals and ongoing legal scrutiny. The stock shows strong fundamentals with revenue growth from $18.83B in 2025 to a projected $20.9B in 2026, net income margin improving to 21.91%, and consistent earnings beats. However, recent news highlights a 20% stock drop and multiple securities fraud investigations related to TurboTax pricing issues, creating investor uncertainty despite a bullish analyst consensus.
The outlook for INTU is cautiously optimistic given its robust financial health and AI-driven growth initiatives, but near-term risks from legal challenges and market sentiment could pressure the stock. Investors should weigh the company's solid profitability and upward earnings trajectory against potential volatility from ongoing investigations and competitive pressures in the fintech software space.
Viatris (VTRS) trades at $17.10, down 1.1% today but maintains a bullish technical outlook with strong moving average signals. The company shows mixed fundamentals with recent earnings beats but negative profitability metrics, while analyst consensus leans toward Hold with a $20 price target. Recent positive developments include FDA acceptance of new drug applications and pipeline progress in biosimilars.
Viatris presents a value opportunity with reasonable P/S and P/B ratios, but faces challenges with negative margins and high debt. The stock's upside potential depends on successful pipeline execution and debt reduction, while risks include competitive pressures and execution missteps in a challenging pharmaceutical market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
